Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK‐875)-Reference-Cited by-同舟云学术

Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK‐875)

Published:2020-12-03 Issue:4 Volume:354 Page:2000275
ISSN:0365-6233
Container-title:Archiv der Pharmazie
language:en
Short-container-title:Arch Pharm

Author:

Lukin Alexey¹,Bakholdina Anna¹,Zhurilo Nikolay¹,Onopchenko Oleksandra²,Zhuravel Elena²,Zozulya Sergey²³^ORCID,Gureev Maxim⁴^ORCID,Safrygin Alexander⁵^ORCID,Krasavin Mikhail⁵^ORCID

Affiliation:

1. Lomonosov Institute of Fine Chemical Technologies MIREA–Russian Technological University Moscow Russian Federation

2. Enamine Ltd. Kyiv Ukraine

3. Taras Shevchenko National University Kyiv Ukraine

4. I. M. Sechenov First Moscow State Medical University Moscow Russian Federation

5. Institute of Chemistry Saint Petersburg State University Saint Petersburg Russian Federation

Funder

Russian Foundation for Basic Research

Publisher

Wiley

Subject

Drug Discovery,Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ardp.202000275

Reference32 articles.

1. The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids

2. Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1

3. Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists

4. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus

5. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016–2019): a patent review

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships;European Journal of Medicinal Chemistry;2024-01

2. 5-Nitrofuran-Tagged Oxazolyl Pyrazolopiperidines: Synthesis and Activity against ESKAPE Pathogens;Molecules;2023-09-07

3. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity;Bioorganic & Medicinal Chemistry Letters;2021-06